C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
Alzheimer's disease is frequently associated with abnormalities in the hypothalamic pituitary adrenal axis. Elevated cortisol levels in Alzheimer's disease may in turn be associated with a more rapid progression of the illness. In addition, elevated cortisol levels may directly contribute to cognitive deficits in Alzheimer's disease. Mifepristone is a potent antagonist of the glucocorticoid receptor and blocks the central actions of cortisol. The purpose of this study is to determine the effects of glucocorticoid receptor blockade with mifepristone on cognition in Alzheimer's disease.
Corcept Therapeutics, 275 Middlefield Road, Menlo Park, California 94025, USA.
Charles
C
DeBattista
Joseph
J
Belanoff
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003072:Cognition Disorders / Q000188:drug therapy / Q000378:metabolism; D004359:Drug Therapy, Combination; D006801:Humans; D015735:Mifepristone / Q000494:pharmacology / Q000627:therapeutic use*; D011965:Receptors, Glucocorticoid / Q000037:antagonists & inhibitors / Q000378:metabolism
D011965:Receptors, Glucocorticoid; D015735:Mifepristone